117
Russia - France
line with the ‘Pharma 2020’ strategy. In
2012, Servier became one of the first
international laboratories to export its
drugs that are manufactured in Russia
to the countries in the CIS. Since 2016,
we have also set up a real platform that
enables us to transfer the competences
and know-how that we have acquired in
Russia to the countries of the Eurasian
Economic Union and to Central Asia.
To remedy certain issues that are
specific to the Russian pharmaceutical
market, we have implemented our
innovative solutions there. Starting in
2011, Servier was the pioneer in Russia
in developing innovative tools for
securing its drugs, such Securistamp,
a coded digital authenticator that is
printed on the drug packaging.
In 2016, Servier also joined the ‘Track
and Trace’ pilot project that was laun-
ched by the Russian authorities. The
goal is to improve patient safety while
guaranteeing total traceability for every
package of medicine sold.
The Servier plant especially produces
treatments for cardiovasculardiseases
and diabetes. What are the needs of
Russian patients? What developments
are expected for Servier?
We produce the Servier drugs that are
sold in Russia locally and most of them
are designed for treating chronic non-
communicable diseases, which are the
leading cause of death in the country.
Our production system ensures total
compliance with our corporate stan-
dards, the international requirements
of good manufacturing practices and
Russian legislative standards.
We have made oncology one of our
priority research areas. In two years,
the place of oncology in R&D has risen
from 14% to 37% today. It should reach
50 % within two years.
We also enable foreign laboratories
that wish to set up business in the
country to produce their innovative
drugs at Servier RUS. For example, our
agreement with the laboratory GSK-
ViiV Healthcare aims at transferring
new technologies to our industrial site
for the production of a triple therapy for
the treatment of AIDS. This project will
contribute to improving access of
Russian patients to innovative and high
quality drugs and is in line with the
Group’s goal to expand its industrial
potential. To this end, Servier is
currently studying new partnerships
with local laboratories.
What will be the Group’s development
strategy in Russia? Howdo you see the
future of the Russian subsidiary?
The Servier Group reinvests 25 % of its
revenues in R&D and employs 2,800
people in three research centres. In
recent years, there have been signifi-
cant successes in the development of
innovative drugs for treating cardiovas-
cular and neuropsychiatric diseases.
Today, our drug portfolio consists of
seventeen products that are sold in the
Russian market and we plan to double
it in the next five years.
Our Business Development is totally in
line with our global approach. It is
focused on our five therapeutic priori-
ties, which are cardiovascular diseases,
diabetes, cancers, immuno-inflamma-
tory diseases and neuropsychiatric
diseases.
Due to the specificities of the local
market, generic medicines (more than
a third of the revenues of the Servier
Group) are a strategic priority: EGIS,
our international specialized subsidia-
ry, has successfully entered the Russia
market.
Finally, our ambition is to make
Servier a committed and recognized
stakeholder. We are involved in many
local projects to find solutions to social
issues.
>
Production unit of Laboratoires Servier in Russia.
Servier
7, Lesnaya st. - 125196 Moscow - Russia
